Rust Coreutils 0.8.0 released with massive performance gains and a new online playground. Learn what's new in uutils coreutils 0.8.0 release.

Despite ongoing developments in head injury protocols, rugby union still faces challenges in achieving accurate, rapid and ...

CoinDesk Research maps five crypto privacy approaches and examines which models hold up as AI improves. Full coverage of ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.37, moving +1.51% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.28%. Elsewhere, the Dow ...

ABSTRACT: Automatic detection of cognitive distortions from short written text could support large-scale mental-health screening and digital cognitive-behavioural therapy (CBT). Many recent approaches ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

This was largely due to news from a rival clincal-stage biotech. Late on Friday, U.K.-based Biodexa announced it had launched a phase 3 clinical trial of its eRapa, an investigational drug that ...